PV Bulletin

Change to Patient Information and Information for Healthcare Professionals Templates

Swissmedic has updated the templates for Patient Information (PI) and Information for Healthcare Professionals (FI), introducing an optional section for instructions for use.

PV Impact Brief

Urgency: HighConfidence: high

What changed

MAHs must use updated PI/FI templates for new submissions and variations, and incorporate the optional 'Gebrauchsanweisungen' section from 1 July 2026.

Why it matters

This change ensures that safety information and instructions for use are clearly presented, improving readability and user-friendliness for patients and healthcare professionals.

Action needed

MAHs must ensure new medicinal product information texts use updated templates by 1 July 2026 and revise existing texts at the earliest opportunity if they include instructions for use.

Relevant for
Regulatory Intelligence LeadLabeling LeadQPPV
Processes impacted
Labeling
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Notice
Policy status
revised
Publication date
2026-07-01
Policy change
Swissmedic has updated the templates for Patient Information (PI) and Information for Healthcare Professionals (FI), adding an optional 'Gebrauchsanweisungen' (instructions for use) section to accommodate redesigned barrier-free access websites.

Key changes

New optional section for instructions for use; updated templates must be used for new medicinal product information texts from 1 July 2026.

Affected workflows

Labeling

PV impact

MAHs must use updated PI/FI templates for new submissions and variations to ensure appropriate presentation of safety information and instructions.

View regulator source

Source document details

Exact policy details

Use of updated templates
1 July 2026
Applies to: Applicable for new medicinal product information texts.
The updated Patient information and Information for healthcare professionals for human medicinal products templates must be used from 1 July 2026 for new medicinal product information texts. · p. 1 · High · Source
Responsibility for readability and user-friendliness
Authored by the authorization holder
Applies to: All authorization holders of human medicinal products
The authorisation holder is responsible for ensuring the Patient information and Information for healthcare professionals are readable and user-friendly. · p. 1 · High · Source
Update requirement for existing products
At the earliest opportunity
Applies to: Medicinal products already authorized
Swissmedic requests authorisation holders for medicinal products whose Patient information and/or Information for healthcare professionals include instructions for use at the end of the document to update the relevant texts using the new templates at the earliest opportunity. · p. 1 · High · Source
Submission of changes if content is altered
Appropriate application must be submitted
Applies to: When content changes are made
This editorial change can be made independently unless changes have been made to the content of the texts. In these cases, an appropriate application must be submitted. · p. 1 · High · Source

Evidence and confidence

Confidence: highSource updated: Jul 1, 2026

Full briefing

Practical implication

MAHs must ensure new medicinal product information texts use updated templates by 1 July 2026 and revise existing texts at the earliest opportunity if they include instructions for use.

Swissmedic mandates that updated templates for Patient Information and Information for Healthcare Professionals be utilized from 1 July 2026 for new submissions and variations. An optional section for instructions for use must be incorporated to enhance presentation and accessibility.

What changed: MAHs must use updated PI/FI templates for new submissions and variations, and incorporate the optional 'Gebrauchsanweisungen' section from 1 July 2026.

Why it matters: This change ensures that safety information and instructions for use are clearly presented, improving readability and user-friendliness for patients and healthcare professionals.

Practical implication: MAHs must ensure new medicinal product information texts use updated templates by 1 July 2026 and revise existing texts at the earliest opportunity if they include instructions for use.

View original source

Published from the Firecrawl policy change extraction pipeline.

Related updates for your role

publicFood and Drug Administration (FDA) · United States · Updated Jun 29, 2026

eMDR System Enhancements - Production Deployment

Urgency: High

Update electronic safety reporting systems and pharmacovigilance databases to implement new rules to ensure all submissions use GENC 3-letter country codes and include the required fields as of July 20, 2026.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicTherapeutics Goods Administration · Australia · Updated Jul 20, 2026

Updates on ISO 14155 and N=1 Therapeutics Discussed by TGA

Urgency: High

Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.

Inspection ReadinessICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Jul 20, 2026

CHMP Draft Agenda for Public Consultation on Thalassaemia and Sickle Cell Disease Guidelines

Urgency: High

Sponsors and MAHs must review and align safety data collection and reporting protocols with the newly adopted guidelines while preparing for implementation of PRAC recommendations stemming from this meeting.

Signal ManagementICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Agenda
Read impact briefarrow_forward
publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Urgency: High

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Checklist
Read impact briefarrow_forward